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AbsTrACT
background Because multiple sclerosis (Ms) is a 
chronic disease causing disability over decades, it is 
crucial to know if the short-term effects of disease-
modifying therapies reported in randomised controlled 
trials reduce long-term disability. This 10-year prospective 
observational study of disability outcomes (expanded 
Disability status scale (eDss) and utility) was set up, 
in conjunction with a risk-sharing agreement between 
payers and producers, to investigate this issue.
Methods The outcomes of the UK treated patients were 
compared with a modelled untreated control based on 
the British columbia Ms data set to assess the long-term 
effectiveness of these treatments. Two complementary 
analysis models were used: a multilevel model (MLM) 
and a continuous Markov model.
results 4862 patients with Ms were eligible for the 
primary analysis (mean and median follow-up times 8.7 
and 10 years). eDss worsening was reduced by 28% 
(MLM), 7% (Markov) and 24% time-adjusted Markov in 
the total cohort, and by 31% (MLM) and 14% (Markov) 
for relapsing remitting patients. The utility worsening 
was reduced by 23%–24% in the total cohort and by 
24%–31% in the RR patients depending on the model 
used. all sensitivity analyses showed a treatment effect. 
There was a 4-year (cI 2.7 to 5.3) delay to eDss 6.0. an 
apparent waning of treatment effect with time was seen. 
subgroup analyses suggested better treatment effects in 
those treated earlier and with lower eDss scores.
Conclusions This study supports a beneficial effect on 
long-term disability with first-line Ms disease-modifying 
treatments, which is clinically meaningful. however the 
waning effect noted requires further study.
InTroduCTIon
Multiple sclerosis (MS) is a major cause of serious 
physical disability in adults of working age. The 
majority of patients start with a relapsing remit-
ting phase (RRMS), which then becomes secondary 
progressive (SPMS) with or without superimposed 
relapses at a median disease duration of 20 years.1 
It is during this latter phase that the majority of the 
disability is manifest.
The first randomised controlled trials (RCT) of 
MS disease-modifying treatments (DMTs) were 
reported in the 1990s.2–5 These led to the licensing 
of three formulations of interferon beta (Betaferon/
Betaseron, Rebif and Avonex) and of glatiramer 
acetate (Copaxone) for RRMS. The licences of 
Betaferon and Rebif were subsequently extended in 
Europe to include patients with relapsing SPMS.6–8
All four treatments were shown, over the period 
of 2–3 years of the trials, to be efficacious in 
reducing relapses (by approximately 30%) and in 
reducing MRI activity, with less robust evidence on 
disability. The most important outcome, that is, the 
long-term effect of treatment on disability, could 
not be addressed within this timescale, and the 
predictive value of short-term treatment outcomes 
on longer term disability remains unproven. Only 
longer term follow-up data can provide informa-
tion on the sustainability of treatment effects and 
on delaying time to loss of independent ambulation.
Because of the uncertainty of the long-term 
benefit, the UK’s National Institute for Health 
and Care Excellence (NICE) in 2002 concluded 
that it was unable to recommend the use of these 
DMTs within the UK National Health Service,9 but 
recognised that these drugs could be cost-effective 
over the longer term if early treatment effects on 
disability persisted. Consequently a novel risk-
sharing scheme (RSS) was set up between the UK 
Department of Health, the pharmaceutical compa-
nies, professional and patient groups to deliver 
these DMTs cost-effectively10 (see online supple-
mentary appendix 1 for details).
A key feature of the scheme was the monitoring 
of disability progression in a cohort of patients to 
test whether observed outcomes were in line with 
those required for cost-effectiveness. This obser-
vational study recruited over 5000 UK patients 
prescribed the interferon-βs and glatiramer acetate 
between 2002 and 2005 and followed them up over 
a 10-year period in order to measure the long-term 
effectiveness of the drugs when compared with a 
modelled natural history cohort. Two yearly anal-
yses were performed and if observed outcomes 
deviated from target by more than an agreed 
margin, the price of the drugs would be adjusted to 
restore cost-effectiveness.
At 2 years the initial Ontario natural history data 
set was deemed not suitable to model the untreated 
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control group because the disability scores had been smoothed,11 
and the British Columbia MS database was selected and vali-
dated.12 13 A second independent analysis model (a multilevel 
model (MLM)) was added14 to corroborate results from the 
Markov model specified in the RSS.15
After 6 years of follow-up,13 the drugs in aggregate showed a 
40% reduction in the rate of deterioration in disability on the 
MLM in patients with relapsing remitting disease (24% on the 
Markov model); this translated into a reduction of 43% (multi-
level) or 42% (Markov) in the rate at which utility worsened, 
which was on track for the cost-effective target.10
The scientific analysis plan for this 10-year analysis16 was 
further revised in line with intention-to-treat principles, with 
additional analyses of (1) subgroups, (2) the influence of time 
on treatment effectiveness and (3) the effect of treatment on the 
time to loss of unaided ambulation. Here we report the final 
results of this study, focusing on the longer term effect of DMTs 
on disability progression.
MeThods
The detailed protocol can be found elsewhere12–14 and the 
following is a summary.
Patient recruitment and follow up
Between May 2002 and July 2005, 72 sites across the UK 
recruited patients with RRMS or SPMS fulfilling the Associa-
tion of British Neurologists (ABN) 2001 criteria for treatment 
(Expanded Disability Status Scale (EDSS) ≤6.5; ≥18 years 
old; two relapses in the last two calendar years).17 Drug selec-
tion reflected clinical practice and was led by individual patient 
and physician choice within the licensed indications in the UK. 
Ten-year follow-up was planned with the annual EDSS18 scores, 
whether treatment was continued or not. Telephone assessments 
were permitted for EDSS values over 6.19
For this final analysis the main outcome was an ‘intention 
to treat’ analysis which included all recruited patients, both 
RRMS and SPMS at baseline, and all follow-up scores including 
those from patients switching to non-scheme DMTs. However, 
subgroup analysis also focused on the RRMS at baseline patients, 
since this was the cohort for which the price adjustment scheme 
was set up.
natural history comparator
The British Columbia MS data set is a population-based data-
base, established in 1980, with the EDSS scored by the MS 
neurologist at outpatient visits.1 Patients (n=978) were identi-
fied who, between 1980 and 1995, fulfilled similar eligibility 
criteria to the RSS cohort. The ‘baseline’ for these patients was 
taken as the first clinic visit at which they fulfilled the criteria. 
Patient information was included only up to the end of 1995, 
after which DMTs were widely available in Canada.
outcomes
For scientific purposes, our primary interest was to compare 
the rate of disability worsening (ie, disease progression) of 
patients treated with DMTs, as observed in the RSS, with that 
in an untreated modelled comparator control group (‘compar-
ison against control’). Disease progression was modelled in the 
patients in the British Columbia data set adjusting for differences 
in prognostic factors (EDSS at baseline, age at onset) between the 
two data sets. The technical details are explained below. Disease 
progression was measured in terms of the accumulation of 
disability (as measured by EDSS) and worsening of quality of life 
(expressed as utility, derived from the EDSS score—see online 
supplementary appendix 2), for eligible and treated patients with 
at least one EDSS score after baseline. Outcomes were expressed 
both as absolute differences between progression observed in the 
RSS treated group and the comparator control group, and the 
relative difference in progression (expressed as a percentage).
The secondary outcomes included the area under the curve 
(a cumulative measure of reduction in disability using the abso-
lute value of area under EDSS–time curve calculated using the 
trapezoid rule) and the delay in the median time required for 
sustained progression to the clinically relevant milestone of 
EDSS 6.0 (needing a stick to walk 100 m), confirmed at least 6 
months with no subsequent lower scores.20
supplementary analyses
A wide range of prespecified sensitivity analyses (online supple-
mentary table 1 and 2) were conducted to assess assumptions 
related to modelling and loss to follow-up. Prespecified subgroup 
analyses allowed us to examine treatment effect by sex, EDSS 
and disease course (RRMS/SPMS) at baseline, disease duration 
and recruitment date. (Patients recruited later in the scheme may 
be more typical of normal clinical practice than those recruited 
earlier, many of whom had been waiting for treatment and had 
more advanced disease.) We also used a variety of methods to 
explore the apparent changes in the treatment effect over time 
(online supplementary appendix 3).
statistical design
In order to calculate the expected progression for untreated 
patients, two independent models were developed, a Markov 
model and an MLM—for further details see online supple-
mentary appendix 4. Both models used data from the natural 
history comparator data set and these were validated in previous 
studies12 14 as being reliable methods for predicting the untreated 
outcome. The essential role of the modelling is to adjust for the 
(relatively slight) differences in baseline characteristics between 
the natural history and RSS data sets.
Markov model
The Markov model uses the annual probabilities of moving 
between EDSS scores (or remaining on the same score) from 
the untreated values derived from the British Columbia data set. 
These probabilities are then applied to the baseline EDSS scores 
of the RSS cohort and to subsequent modelled EDSS states over 
10 years to give the expected EDSS progression for untreated 
patients. The difference between the expected untreated and 
observed RSS treated mean EDSS score represents the treatment 
effect.
Estimation was by the Jackson continuous time method21 using 
age at onset dichotomised at the median as a predetermined 
covariate.12 Because the assumption in the Markov model is that 
the transition probabilities from one specific EDSS score do not 
vary over time (and this assumption is unlikely to be precise), we 
used a ‘time-varying’ model, with separate transition matrices 
estimated for the first 2 years after baseline and for the rest of 
the follow-up period, as a sensitivity analysis. CIs on projections 
using the Markov model are derived by bootstrapping.
Multilevel model
The MLM22 23 uses the mean trajectory for the whole popu-
lation, the variation of individual trajectories about this mean 
and the fluctuation of individual EDSS scores about the trend 
for each individual. The untreated values were again derived 
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Figure 1 consolidated standards of Reporting Trials diagram for all 
patients in the UK Ms risk-sharing scheme. eDss, expanded Disability 
status scale; Ms, multiple sclerosis; RRMs, relapsing remitting Ms.
Table 1 Outcomes of the primary analysis: primary analysis cohort, including patients with SPMS at baseline (n=4862; average follow-up 8.7 
years)
outcome measure Model
Actual progression
(95% CI)
Predicted progression 
(natural history)
(95% CI)
Absolute treatment effect
(predicted natural history 
progression less actual)
(95% CI)
relative rate of disease 
progression
(actual divided by predicted 
natural history) (95% CI)
(1) (2) (3)=(2–1) (4)=(1)/(2)
Rounded EDSS* Markov 1.53 (1.48 to 1.58) 1.65 (1.63 to 1.67) 0.12 (0.07 to 0.17) 93% (90% to 96%)
EDSS* MLM 1.53 (1.47 to 1.58) 2.13 (2.11 to 2.15) 0.61 (0.55 to 0.66) 72% (69% to 74%)
Utility Markov 0.122 (0.117 to 0.127) 0.161 (0.159 to 0.163) 0.039 (0.034 to 0.044) 76% (73% to 79%)
MLM 0.122 (0.117 to 0.127) 0.159 (0.156 to 0.162) 0.037 (0.031 to 0.042) 77% (74% to 80%)
*For the Markov model, half-integer EDSS states are combined with the next lower integer EDSS state. Calculations with the MLM using rounded EDSS values gave almost 
identical results to those using the full EDSS scale.
EDSS, Expanded Disability Status Scale; MLM, multilevel model; SPMS, secondaryprogressive multiple sclerosis.
from the British Columbia data set. The model is applied to 
the baseline data for patients in the RSS data set to predict the 
EDSS progression without treatment for each individual. The 
projections are then combined across all individuals to produce 
a predicted untreated mean EDSS progression for the whole RSS 
cohort. This is then compared with the observed data in the RSS 
(the ‘comparison against control’) to estimate the absolute treat-
ment effect.
For consistency with the Markov model,12 age at onset (binary 
variable) was included as the only covariate after previous 
covariate modelling found this to be sufficient. Validation of 
the model14 24 was undertaken on the British Columbia cohort 
(internal validation) and also using a natural history data set 
from the University Hospital of Wales (external validation). 
Bootstrapping was used to derive 95% CIs.
Time to sustained EDSS 6.0
To estimate the time to sustained EDSS 6.0, a parametric 
(Weibull) model was fitted to the British Columbia Multiple 
Sclerosis (BCMS) data, with gender and baseline EDSS as covari-
ates. A similar model was fitted to the RSS data. To adjust for 
differences in baseline distributions, the strata were combined 
using as weights the proportion of patients at baseline in the RSS 
data set (see online supplementary appendix 5 for details).
Governance of the study
An independent Scientific Advisory Group consisting of Pelham 
Barton, Yoav Ben-Shlomo, Richard Gray and chaired by Richard 
Lilford developed and approved the statistical analysis plan. 
Representation from the authors, NICE, the MS Trust and the 
Department of Health attended the Scientific Advisory Group 
meetings. The representatives from each company were observers 
at the Scientific Advisory Group meetings but had no role in the 
data collection, analysis or preparation of the manuscript.
resulTs
Patient disposition and characteristics
Out of 5602 patients registered for recruitment, 4986 were 
consented and eligible for treatment, began treatment, and had 
baseline assessments. Of these 4986, 4862 (97.5%) had at least 
one follow-up EDSS score and were included in the primary 
analysis. Of these, 17% switched to non-scheme drugs during 
follow-up, with the majority using natalizumab or fingolimod, 
and 18% discontinued treatment during the study. The Consoli-
dated Standards of Reporting Trials diagram is shown in figure 1 
(details in online supplementary table 2). The median follow-up 
was 10 years, the mean follow-up was 8.7 years and 77% of the 
primary analysis group had a minimum of 9 years of follow-up 
data. An additional 2.6% had late year 10 data collected, used in 
the sensitivity analysis.
The baseline characteristics for the analysis cohort were 
similar to those in the British Columbia data set (online supple-
mentary table 3), although RSS patients had on average slightly 
higher EDSS and age at onset and thus slightly longer disease 
duration on first assessment; however, the models adjust for 
baseline EDSS scores and age of onset.
Primary outcomes
The primary outcomes are shown in table 1. The absolute 
10-year treatment effect was a reduction of 0.61 using the MLM 
(95% CIs 0.55 to 0.66) and of 0.12 in mean EDSS using the 
Markov model (95% CIs 0.07 to 0.17). The corresponding rela-
tive reduction in progression was 28% (95% CIs 26% to 31%) 
for the MLM and 7% (95% CIs 4% to 10%) for the Markov 
model. However, using the time-varying Markov model, the 
effect size closely mirrors the MLM results (see below). In utility 
terms, the reduction in progression was 23% (95% CIs 20% to 
26%) on the MLM and 24% (95% CIs 21% to 27%) on the 
Markov model. Figure 2A,B shows how the observed disability 
progression deviates over the 10-year period from that expected 
for untreated patients (the comparator control group) for the 
MLM.
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Figure 2 comparison against control results using the MLM model: disability outcomes over 10 years in Rss patients and in the untreated comparator 
control group, for the whole cohort (a) eDss progression and (B) utility progression, and for the patients with RRMs at baseline (c) eDss progression and 
(D) utility progression. eDss, expanded Disability status scale; MLM, multilevel model; RRMs, relapsing remitting multiple sclerosis; Rss, risk-sharing scheme.
Figure 3 Time to sustained eDss 6.0 in Rss treated patients and in 
the untreated comparator control group. eDss, expanded Disability status 
scale; Rss, risk-sharing scheme.
secondary outcomes
The cumulative benefit accrued over the first 10 years of treat-
ment for the whole cohort (the area under the curve for the 
full period) was 1.3 EDSS years (95% CIs 0.9 to 1.6—estimates 
available only for the Markov model). The estimated median 
time for the whole cohort to reach sustained EDSS 6.0 using 
the Weibull model was 12.5 years (95% CIs 11.8 to 13.3); this 
compares with 8.4 years (95% CIs 7.4 to 9.6) for untreated 
patients (figure 3), indicating that treatment is associated with a 
delay of 4.0 years (95% CIs 2.7 to 5.3) in reaching this relevant 
disability endpoint.
sensitivity analyses
The results of the sensitivity analyses are shown in table 2 and 
online supplementary table 4. As expected, excluding EDSS 
scores after patients switched to alternative treatments—effec-
tively censoring later data from patients on a worse trajectory—
makes the results appear more favourable to the DMTs. Imputing 
missing values in the RSS data set makes relatively little differ-
ence to the outcomes, except in the deliberately extreme case 
(greater than a standard worse case scenario) in which we added 
0.5 EDSS points to each imputed value (on average, doubling 
the imputed progression since the last available score), where 
the magnitude of the treatment effect on EDSS was reduced by 
roughly a quarter. In contrast, a variant in which we ‘enriched’ 
the British Columbia data set by imputing additional values for 
patients with relatively sparse follow-up and re-estimated the 
transition probabilities resulted in a substantially greater treat-
ment effect. Finally, using variant of the Markov model with 
time-varying transition probabilities resulted in a greater treat-
ment effect, with a much closer agreement for the EDSS results 
to those from the MLM. Online supplementary appendices 6 
and 7 provide further details.
subgroup analyses
Estimated treatment effects were rather larger for the subset of 
patients with RRMS at baseline (table 3, figure 2C,D; MLM), 
with 31% and 14% reduction in EDSS worsening and 24% and 
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Table 2 Sensitivity analyses (EDSS basis)
Variant
Patients 
(n)
Mean years Absolute treatment effect (edss) relative treatment effect (edss)
Follow-up
on 
treatment Markov model MlM Markov model MlM
Primary analysis 4862 8.7 7.0 0.12 (0.07, 0.17) 0.61 (0.55, 0.66) 93% (90%, 96%) 72% (69%, 74%)
RRMS-only subgroup 4217 8.9 7.3 0.25 (0.20, 0.31) 0.68 (0.62, 0.74) 86% (83%, 89%) 69% (67%, 72%)
Supplementary/sensitivity analyses (including patients with SPMS at baseline except where noted)
Excluding EDSS scores recorded after a patient has switched to a non-scheme DMT*
Primary analysis cohort 4799 8.0 6.4 0.13 (0.08, 0.19) 0.59 (0.53, 0.64) 91% (88%, 95%) 70% (68%, 73%)
RRMS-only subgroup† 4157 8.1 6.7 0.26 (0.21, 0.32) 0.66 (0.60, 0.72) 84% (81%, 88%) 68% (65%, 71%)
Excluding EDSS scores recorded after a patient has switched to any other DMT*
Primary analysis cohort 4475 7.0 5.7 0.16 (0.11, 0.22) 0.57 (0.52, 0.62) 88% (84%, 92%) 68% (65%, 70%)
RRMS-only subgroup 3871 7.0 5.9 0.29 (0.23, 0.35) 0.64 (0.59, 0.70) 80% (76%, 84%) 65% (62%, 68%)
Imputation—Markov model, using imputed values derived from the MLM
‘on treatment’ assumption 4862 9.9 7.7 0.12 (0.07, 0.17) NA 93% (91%, 96%) NA
‘off treatment’ assumption 4862 9.9 7.0 0.10 (0.04, 0.15) NA 95% (92%, 98%) NA
Imputation—multilevel model
‘on treatment’ assumption 4862 9.9 9.9 NA 0.67 (0.62, 0.72) NA 72% (70%, 74%)
‘off treatment’ assumption
Single imputation 4862 9.9 9.9 NA 0.65 (0.59, 0.70) NA 73% (70%, 75%)
Multiple imputation 4862 9.9 9.9 NA 0.64 (0.59, 0.70) NA 73% (71%, 75%)
Single imputation +0.5 EDSS points for each 
imputed value
4862 9.9 9.9 NA 0.48 (0.43, 0.53) NA 80% (78%, 82%)
Supplement RSS data with imputed values 
derived from out-of-window year 10 scores‡
4862 8.9 7.0 0.12 (0.07, 0.18) ‡ 93% (90%, 96%) ‡
Use transition matrices from BCMS data set supplemented by imputing additional data for patients with sparse follow-up‡
Including patients with SPMS at baseline 4862 8.7 7.0 0.28 (0.23, 0.34) ‡ 84% (81%, 87%) ‡
Excluding patients with SPMS at baseline 4217 8.9 7.3 0.43 (0.37, 0.49) ‡ 78% (75%, 81%) ‡
Alternative Markov model with time-varying 
natural history transition matrices
4862 8.7 7.0 0.48 (0.42, 0.53) NA 76% (74%, 79%) NA
Year 1 baseline (see online supplementary 
appendix 8)
4360 7.9 6.2 0.07 (0.02, 0.12) 0.43 (0.38, 0.48) 95% (92%, 99%) 77% (74%, 79%)
*Patients switching before year 1 are also excluded from the analysis.
†This was the primary analysis for the interim year 6 analysis.
‡These variants were only carried out for the Markov model.
DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; MLM, multilevel model; NA, not applicable; RRMS, relapsing remitting multiplesclerosis; RSS, risk 
sharing scheme; SPMS, secondary progressive multiple sclerosis; BCMS, British Columbia Multiple Sclerosis.
Table 3 Main outcomes, patients with RRMS at baseline: subgroup of patients with RRMS at baseline (n=4217; average follow-up 8.9 years)
outcome measure Model
Actual progression
(95% CI)
Predicted progression
(natural history)(95% CI)
Absolute treatment effect
(predicted natural history 
progression less actual)
(95% CI)
relative rate of disease 
progression
(actual divided by predicted 
natural history)(95% CI)
(1) (2) (3)=(2−1) (4)=(1)/(2)
Rounded EDSS* Markov 1.55 (1.49 to 1.61) 1.80 (1.78 to 1.83) 0.25 (0.19 to 0.31) 86% (83% to 89%)
EDSS* MLM 1.55 (1.49 to 1.61) 2.23 (2.21 to 2.25) 0.68 (0.62 to 0.74) 69% (67% to 72%)
Utility Markov 0.113 (0.108 to 0.119) 0.164 (0.163 to 0.166) 0.051 (0.046 to 0.056) 69% (66% to 72%)
MLM 0.113 (0.108 to 0.118) 0.150 (0.148 to 0.152) 0.037 (0.031 to 0.042) 76% (72% to 79%)
*For the Markov model, half-integer EDSS states are combined with the next lower integer EDSS state. Calculations with the MLM using rounded EDSS values gave almost 
identical results to those using the full EDSS scale.
EDSS, Expanded Disability Status Scale; MLM, multilevel model; RRMS, relapsing remitting multiple sclerosis.
31% reduction in utility worsening (MLM and Markov models, 
respectively).
Other prespecified subgroup analyses using the Markov model 
(tables 4 and 5, and online supplementary table 5) suggest that 
greater treatment effects are associated with a lower EDSS score 
at baseline, patients with shorter time from disease onset, women 
rather than men, patients on treatment throughout rather than 
those who come off treatment, and patients recruited later in the 
scheme. The MLM however did not find evidence of a reduction 
in treatment effect with increasing baseline EDSS.
Changes over time
Table 6 shows how the main outcomes using the MLM model 
change when the primary analysis is repeated with years 2, 4, 6, 
8 and 10 as the end year. The results suggest that, although the 
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Table 5 Other subgroup analyses (Markov model only)
Population n
Mean years Mean edss utility
At risk
on 
treatment
baseline
edss
Absolute treatment 
effect
relative rate of 
progression
Absolute treatment 
effect
relative rate of 
progression
Primary analysis population 4862 8.7 7.0 3.18 0.12 (0.07, 0.17) 93% (90%, 96%) 0.039 (0.034, 0.044) 76% (73%, 79%)
One-way analyses
On treatment throughout 2855 8.7 8.7 3.02 0.46 (0.39, 0.53) 73% (69%, 77%) 0.073 (0.067, 0.079) 55% (51%, 58%)
Ever off-treatment 2007 8.8 4.6 3.40 −0.36 (−0.44, −0.28) 123% (118%, 128%) −0.010 (−0.018, −0.001) 106% (101%, 111%)
By gender
Male 1224 8.6 6.8 3.19 −0.12 (−0.23, 0.00) 107% (100%, 114%) 0.013 (0.002, 0.024) 92% (85%, 99%)
Female 3638 8.8 7.0 3.17 0.20 (0.14, 0.26) 88% (84%, 92%) 0.048 (0.042, 0.053) 71% (67%, 74%)
Baseline at or before 28 
February 2003
997 8.7 7.0 3.35 0.03 (−0.09, 0.14) 98% (91%, 106%) 0.035 (0.024, 0.046) 78% (71%, 85%)
Baseline after 28 February 
2003
3865 8.8 7.0 3.13 0.14 (0.09, 0.20) 91% (88%, 95%) 0.040 (0.034, 0.045) 75% (72%, 79%)
Baseline at or before 31 
August 2003
2351 8.7 6.9 3.32 0.02 (−0.06, 0.10) 99% (94%, 103%) 0.033 (0.025, 0.040) 79% (75%, 84%)
Baseline after 31 August 
2003
2511 8.8 7.0 3.05 0.21 (0.14, 0.29) 88% (83%, 92%) 0.044 (0.037, 0.052) 73% (69%, 77%)
Disease duration at baseline
≤3 years 1251 8.8 7.3 2.46 0.45 (0.33, 0.57) 77% (71%, 83%) 0.060 (0.050, 0.070) 65% (59%, 71%)
>3 years 3611 8.7 6.9 3.43 0.00 (−0.05, 0.06) 100% (96%, 103%) 0.032 (0.026, 0.037) 80% (76%, 84%)
≤6 years 2295 8.8 7.2 2.67 0.32 (0.24, 0.40) 83% (78%, 87%) 0.051 (0.043, 0.058) 70% (65%, 74%)
>6 years 2567 8.7 6.8 3.64 −0.06 (−0.12, 0.01) 104% (99%, 108%) 0.028 (0.022, 0.035) 82% (78%, 86%)
Two-way analyses
Disease duration ≤3 years and:
Baseline EDSS ≤3.5 981 8.9 7.5 1.80 0.60 (0.47, 0.73) 73% (67%, 79%) 0.068 (0.058, 0.079) 61% (55%, 67%)
Baseline EDSS 4–5.5 199 8.4 6.7 4.41 0.00 (−0.29, 0.28) 100% (74%, 127%) 0.039 (0.009, 0.068) 74% (56%, 94%)
Baseline ≥EDSS 6 71 8.0 5.7 6 −0.35 (−0.76, 0.05) 209% (83%, 338%) 0.001 (−0.050, 0.051) 100% (65%, 135%)
Disease duration >3 years and:
Baseline EDSS ≤3.5 1959 9.0 7.4 2.12 0.23 (0.14, 0.31) 90% (85%, 94%) 0.044 (0.036, 0.051) 73% (69%, 78%)
Baseline EDSS 4–5.5 1076 8.6 6.7 4.43 −0.14 (−0.23, −0.04) 112% (104%, 121%) 0.038 (0.027, 0.048) 76% (69%, 82%)
Baseline ≥EDSS 6 576 8.0 5.4 6 −0.48 (−0.59, −0.37) 236% (204%, 268%) −0.021 (−0.038, −0.004) 114% (103%, 125%)
EDSS, Expanded Disability Status Scale.
Table 6 Variation of the treatment effect with year of analysis (MLM)
Analysis
relative progression rate (%) at year:
2 4 6 8 10
Primary analysis cohort
EDSS basis (95% CI) 47% (41% to 52%) 58% (54% to 62%) 66% (63 to 69%) 71% (68 to 74%) 72% (69 to 74%)
Utility basis (95% CI) 36% (31% to 41%) 55% (51% to 60%) 68% (64 to 72%) 76% (73 to 80%) 77% (743 to 80%)
RRMS-only subgroup
EDSS basis (95% CI) 42% (36% to 48%) 55% (51% to 59%) 63% (60% to 66%) 69% (66% to 72%) 69% (67% to 72%)
Utility basis (95% CI) 28% (22% to 34%) 50% (45% to 55%) 62% (58% to 66%) 74% (70% to 78%) 76% (72% to 79%)
EDSS, Expanded Disability Status Scale; MLM, multilevel model; RRMS, relapsing remitting multiple sclerosis.
treatment effect continues throughout the follow-up period, 
it becomes progressively smaller. We explored this through 
a number of prespecified supplementary analyses using both 
models, including the version of the Markov model with time-
variant transition probabilities. The results (online supplemen-
tary appendix 8) confirm this trend of a large initial effect—in 
the first year or two after treatment initiation—followed by a 
smaller continuing effect. A sensitivity analysis using year 1 as 
the baseline (table 2 and online supplementary table 4) also 
showed a positive but smaller treatment effect.
dIsCussIon
Main findings
Our findings show a clinically significant treatment effect main-
tained at 10 years, on both EDSS and quality of life outcomes, 
with a meaningful delay to sustained loss of unaided ambulation 
of around 4 years in an already impaired cohort at treatment 
onset (median EDSS 3.5).
Our analysis also highlighted a gradual attenuation of the 
treatment effect over time, or perhaps a large initial effect 
followed by a more modest continuing effect. The treatment 
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effects appeared larger for patients with RRMS, those who start 
treatment earlier in their disease course and for women. The 
evidence for the effect of baseline EDSS on the treatment effect 
is less clear.
Methodological issues
This unique study addresses an important issue related to the 
long-term impact of the first-generation DMTs, which was not 
possible to address by a conventional RCT. By establishing a 
novel RSS between the manufacturers and payers, we were able 
to collect high-quality long-term data on disease progression on 
a treated cohort and use historical data on untreated patients to 
construct a comparison control group.
Given the inevitable limitations of observational data, our 
study has important strengths. The RSS cohort is one of the 
largest cohorts ever used in a study of this type, with over 42 000 
patient years of data, with 9 years or more of data for nearly 80% 
of patients—a dropout rate over a decade comparable with that 
seen in recent 2-year treatment trials.25 26 Moreover these results 
reflect the ‘real world’ performance of the DMTs and include 
the effects of patients discontinuing treatment, and may be more 
generalisable than estimates from highly selected short-term RCT 
populations. Our natural history comparator, from the British 
Columbia data set, is also the largest and most complete data set 
of untreated patients available for MS research.1 We used two 
completely independent modelling techniques, with comple-
mentary strengths and weaknesses: the multilevel repeated 
measures model can more easily take account of variations in the 
rate of disease progression between individual disease trajecto-
ries, whereas the Markov model predicted more accurately the 
number of patients at high EDSS levels which largely determine 
changes in mean utility (see (online supplementary appendix 
4). A third model, used for the survival analysis, confirmed the 
finding of a clinically significant treatment effect on time to loss 
of unaided ambulation.
We have implemented ‘intention to treat’ principles, adapting 
the methods of our 6-year study13 to include all eligible and 
consented patients with MS prescribed these DMTs, including 
those with SPMS as well as RRMS at baseline, and data from 
patients who switched to different DMTs—including non-scheme 
DMTs—during follow-up. We believe therefore that we have 
mitigated an important source of potential bias. Naturally, the 
possibility of bias from incomplete follow-up remains, but we 
have tested this by extensive sensitivity analyses with imputa-
tion of missing values. In addition, the patterns of follow-up 
seem broadly similar between the RSS and the British Columbia 
cohorts,13 so any residual biases are likely to offset one another 
(see online supplementary appendix 7). If anything, our results 
may be biased against a treatment effect because we used tele-
phone questionnaires in the UK cohort to capture data from 
patients with high EDSS scores who were unable to attend clinic, 
whereas there was no equivalent for the BCMS cohort. Our 
models are designed to adjust for the (relatively small) differ-
ence in baseline characteristics between the British Columbia 
and RSS data sets, but if this adjustment is imperfect this would 
be expected to bias the results against the treatment effect since 
RSS patients had on average marginally worse prognostic factors 
than British Columbia patients.
There are several other potential biases that must be consid-
ered before assuming a causal explanation for the DMTs that 
may have resulted in differences in the natural history of the two 
cohorts unrelated to treatment.
Geographical differences
Could our UK patients have a milder form of MS than the natural 
history British Columbia patients? Although British Columbia 
is more ethnically diverse, MS still predominates in Europeans 
there.27 More direct evidence demonstrated similar untreated 
trajectories by using our Canadian data set to reproduce accu-
rately 10-year outcomes in a Welsh untreated MS cohort.24
Temporal differences
Could untreated patients with MS have a slower disease progres-
sion than they used to? This concept has been supported by the 
observation that the relapse rates in the placebo arms of RCTs 
have been reducing. This is likely to be due to other reasons 
however. Now DMTs are widely available, ethical consider-
ations make it likely that patients with more active disease are 
prescribed MS drugs rather than risk being allocated to a placebo 
arm. Additionally the later trials introduced early rescue therapy 
options and stricter relapse definitions, which would also reduce 
relapse rates recorded.28 Population-based cohorts are less likely 
to be biased by selection, and there is no evidence for a better 
prognosis in recent MS cohorts from British Columbia29 nor 
Wales (Neil Robertson, personal communication).
Confounding by indication
Could treatment decisions and clinical outcomes be confounded 
by variables such as disease severity and comorbidity, as seen 
in contemporary treated and untreated comparisons? This is 
not relevant in this study because there was no treated versus 
untreated comparison from within a single cohort. The BCMS 
patients were selected using the same inclusion criteria applied 
to the UK patients. Additionally both analysis methods adjusted 
for baseline EDSS and age at entry, and adding other covari-
ates made little difference to the outcomes.12 Previous results 
from the British Columbia data20 30 demonstrated that indica-
tion bias may be important when comparing with contemporary 
untreated patients,20 because untreated patients differed, having 
a milder disease even though fulfilling the same baseline criteria 
for treatment. When the authors compared treated patients with 
historical controls as in our study, they showed a trend towards a 
treatment benefit on time to reach EDSS 6.0 (relative risk 0.77, 
CI 0.58 to 1.02), which is comparable with our results consid-
ering they had a much smaller treated cohort (n=868 vs 4986) 
with shorter follow-up time (mean 5.2 and median 5.1 years vs 
8.7 and 10 in our study). The use of marginal structured Cox 
modelling (which included the contemporary untreated patients) 
did not change interpretation of findings.30
Selection bias
UK patients eligible for DMTs prior to 2002 but who progressed 
rapidly so they were no longer eligible would have been excluded. 
This bias would favour a treatment effect. Working against a 
treatment effect is the exclusion of those who were previously 
eligible but were no longer active enough to be included. A bias 
against a treatment effect might have occurred due to the pres-
ence of prevalent as well as incident ABN eligible patients, which 
would have included patients with later disease being treated, 
and it is possible that DMTs may be less effective later on in the 
disease course. Indeed our results suggested a greater treatment 
effect when excluding patients recruited in the first 18 months 
(once the backlog of prevalent patients had been entered). It is 
also reassuring that disease duration at study entry was almost 
identical for both data sets (table 3).
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Other methodological issues worth considering are the use 
of the EDSS as the main outcome measure and the require-
ments for the EDSS scoring. Although the EDSS is not sensi-
tive to change over the shortterm and focuses on mobility, it 
is the most widely used and accepted measure of disability in 
MS. Using this measure also allows us to convert the outcome to 
quality of life measures for cost-effectiveness calculations and to 
assess whether our results are plausible by comparing the results 
with other studies. The clinicians in our study did not undergo 
formal EDSS training as is required in clinical trials, rather the 
EDSS was collected within the routine clinical setting. Sites were 
instructed to use the same clinician to perform the EDSS over 
time where possible, and it was performed mainly by neurolo-
gists with expertise in MS. This was similar to the way the British 
Columbia natural history data set EDSS measurements were 
performed and thus comparable. The interobserver variability 
in our study was previously reported31 to have a kappa value of 
0.59, 0.71 and 0.85: for full agreement, within 0.5 and within 
1.0 EDSS scores, respectively, and it is expected that the intraob-
server variability is even better.
On balance, therefore, we consider that there are sound 
reasons for believing that these results represent a true treatment 
effect. These reasons include the good agreement between our 
estimates of the absolute treatment effect at year 2 of a mean 
EDSS difference of 0.2213 and those derived from a meta-anal-
ysis of RCTs which gave a mean EDSS difference of 0.2532; the 
generally good agreement between two very different modelling 
approaches (particularly when the Markov models allows time 
to be included in the model); the adjustments included in each 
model to allow for the (relatively small) differences in baseline 
characteristics between the British Columbia and RSS data sets; 
and the use of a wide range of sensitivity analyses to test for 
possible residual sources of bias.
Implications for the treatment of Ms
Assessing the longer term effectiveness of treatment is vital in 
considering the cost-effectiveness of expensive treatments for 
chronic conditions, but RCTs have not and cannot address this 
in MS where disability is acquired over many years. We have 
performed the only prospective long-term study of the treatment 
effect of MS DMTs, and have managed to recruit and retain a very 
large cohort (with higher levels than many short-term RCTs). 
Our results show that the benefits seen in the short term for these 
drugs are maintained over a 10-year period, although the treat-
ment effect appears to decrease over time and may not justify 
the prices for these drugs in some healthcare systems particularly 
where the drug costs are higher.33 This apparent waning effect 
would be consistent with the recent meta-analysis34showing an 
inverse age-dependent association with efficacy. Because age, 
disease duration and EDSS scores are all inter-related and the 
latter two were associated with the treatment effect size in our 
study, it is not clear what is the driving factor. Although newer 
treatments are now available and are often preferred because of 
greater efficacy or ease of administration, their cost-effectiveness 
has in turn been assessed by NICE using incremental compar-
ison with these first-generation drugs and more recently in direct 
head-to-head studies now that placebo studies are regarded as 
unethical. Thus the results of the MS RSS will have important 
consequences for assessing the cost-effectiveness of subsequent 
currently licensed and future drugs for MS.
Our finding that the treatment effect of these drugs is atten-
uated over time could have important implications for clin-
ical practice, both for MS and perhaps for other longer term 
conditions. It might now be ethical to conduct an RCT to deter-
mine whether dicontinuation of treatment—after a given period 
on treatment, or after reaching a given level of disability—offers 
any disadvantage over continuing treatment. An RCT is currently 
under way to assess the effects of withdrawing treatment in older 
patients with MS who have had no relapses or new brain lesions 
for at least 5 years.35 Future trials of treatments for MS could be 
designed so that one arm receives treatment for an initial period 
and then discontinues treatment. On the basis of our findings, 
it might be more cost-effective—and ultimately in the interests 
both of patients with MS and of patients with other conditions—
to intervene earlier in the disease course, rather than to persist 
with treatment for long periods.
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